Leadership & Pay ·
On August 21, 2026, the Board of Directors adopted a new Severance and Change in Control Program for eligible U.S.…
RCKTRocket Pharmaceuticals, Inc.
On August 21, 2026, the Board of Directors adopted a new Severance and Change in Control Program for eligible U.S. employees, superseding prior arrangements. The company also entered into executive employment agreements with CEO Gaurav Shah (annual base salary $674,856) and General Counsel Martin Wilson ($547,313), while amending COO Christopher Stevens' agreement to provide 12 months of severance benefits upon qualifying termination without cause or for good reason. These arrangements include change-in-control protections and are contingent on the execution of a release of claims. Rocket Pharmaceuticals, Inc. operates in the biotechnology industry, developing gene therapies for rare genetic diseases.